Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases
Journal of Inherited Metabolic Disease · 2025-09 · 48 (5)
DOI: 10.1002/jimd.70078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 18.08.2025. Verfasst von Sonam Gurung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Great Ormond Street Institute of Child Health, University College London, London, UK. Hauptthemen laut MEDLINE: Genetic Therapy, RNA, Messenger, Metabolic Diseases, Liver Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Hospital Charity, Medical Research Council.
Abstract (Originalsprache)
mRNA encapsulated in lipid nanoparticles (LNPs) provides a dual revolution in the field of gene therapy. mRNA brings fleeting efficacy and the possibility to adjust the therapy to clinical needs. LNP, as a non‐viral vehicle with flexible organ‐targeting, overcomes most immune complications of viral gene therapy. mRNA‐LNP has rapidly progressed from preventive medicine and vaccine applications to therapeutic use, especially in inherited metabolic diseases (IMDs). Given their natural tropism for liver uptake, this platform has been utilised successfully in numerous preclinical programmes. Early phase clinical trials are recruiting to assess safety and efficacy in liver IMDs. Here, we provide the latest update on mRNA and LNP technologies, preclinical studies and clinical trials targeting IMDs, safety considerations with a spotlight on infusion‐related reactions and safety modelling. We discuss the future directions of therapeutic mRNA‐LNP in IMDs and the right clinical use of this adjustable therapy, still to be defined. The versatility of this technology is appealing, with multiple clinical applications as bridge, long‐term cure, rescue, or adjuvant therapy. mRNA‐LNP for gene editing/insertion is an alternative approach for one‐off cure. Translating various successful preclinical programmes in patients remains an unsolved limitation. mRNA‐LNP can be tuned according to the patient's needs and is the next step in personalised medicine and individualised gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Great Ormond Street Institute of Child Health, University College London, London, UK.
- National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK.
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
ORCID-Profile: Julien Baruteau
Förderung
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Great Ormond Street Hospital Charity
- Medical Research Council
- Citrin Foundation
Zitieren
APA
Gurung, S., Perocheau, D., Ghosh, R., Hart, S. L., & Baruteau, J. (2025). Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases. Journal of Inherited Metabolic Disease, 48(5). https://doi.org/10.1002/jimd.70078
Vancouver
Gurung S, Perocheau D, Ghosh R, Hart SL, Baruteau J. Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases. Journal of Inherited Metabolic Disease. 2025;48(5). doi:10.1002/jimd.70078
BibTeX
@article{Gurung2025,
author = {Gurung, Sonam and Perocheau, Dany and Ghosh, Roopkatha and Hart, Stephen L and Baruteau, Julien},
title = {Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {5},
doi = {10.1002/jimd.70078}
}
EUVIMED